Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm, Residual × inavolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Solid Tumors 1 PIK3CA-Mutated Cancers 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 HER2-positive Breast Cancer 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

Cyclophosphamide 7 venetoclax 5 fludarabine 5 Azacitidine 5 Cytarabine 4 Blood Specimen Collection 4 daratumumab 3 blinatumomab 3 Daunorubicin 3 fludarabine phosphate 2 Liquid Biopsy 2 Lenalidomide 2 Idarubicin 2 Gemtuzumab 2 Capecitabine 2 Busulfan 2 trastuzumab deruxtecan 1 tislelizumab 1 thymoglobulin 1 tetrathiomolybdate 1 talquetamab 1 tagraxofusp 1 sugemalimab 1 sacituzumab govitecan 1 relugolix 1 pembrolizumab 1 pegaspargase 1 palbociclib 1 obinutuzumab 1 ivosidenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡